Loading…
TScan Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -96.1% over 5Y.
today you would have $40.77▼ -95.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.00 | $3.04 | $5.83 | $1.55 | |
| P/S | 9.4x | 5.5x | 61.1x | 13.2x | 2.8x |
| P/B | 0.6x | 0.5x | 0.7x | 1.8x | 0.4x |
| EPS | -$1.00 | -$1.14 | -$1.36 | -$2.75 | |
| Profit margin | -873.04% | -1256.81% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TILInstil Bio, Inc. | $7.58 | — | 0.5x | — | -25.33% | $51.41M |
| MDAISpectral AI, Inc. | $1.57 | — | — | — | — | $50.53M |
| MREOMereo BioPharma Group plc | $0.32 | — | 1.8x | — | -67.85% | $50.51M |
| PRPOPrecipio, Inc. | $28.85 |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Company description provided by Yahoo Finance.
| -4527.66% |
| -423.86% |
| -489.26% |
| ROE | -62.87% | -105.40% | -52.91% | -59.14% | -66.60% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 3.5x |
| — |
| -8.98% |
| $51.65M |
| ELOXEloxx Pharmaceuticals, Inc. | $15.07 | 4.7x | 1.3x | — | — | $51.79M |
| NEPHNephros Inc | $4.55 | 28.4x | 4.1x | — | 16.10% | $49.41M |